XML 16 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2023
Feb. 20, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Trading Symbol APLS    
Entity Registrant Name APELLIS PHARMACEUTICALS, INC.    
Entity Central Index Key 0001492422    
Current Fiscal Year End Date --12-31    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   120,581,749  
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Public Float     $ 10.7
Entity Current Reporting Status Yes    
Entity File Number 001-38276    
Entity Tax Identification Number 27-1537290    
Entity Address, Address Line One 100 Fifth Avenue    
Entity Address, City or Town Waltham    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02451    
City Area Code 617    
Local Phone Number 977-5700    
Entity Interactive Data Current Yes    
Security 12b Title Common Stock, $0.0001 par value per share    
Security Exchange Name NASDAQ    
Entity Incorporation, State or Country Code DE    
Document Annual Report true    
Document Transition Report false    
Document Financial Statement Error Correction false    
ICFR Auditor Attestation Flag true    
Auditor Name Deloitte & Touche LLP    
Auditor Firm ID 34    
Auditor Location Boston, Massachusetts    
Documents Incorporated by Reference

The registrant intends to file a definitive proxy statement pursuant to Regulation 14A in connection with its 2024 Annual Meeting of Stockholders within 120 days of the end of the registrant’s fiscal year ended December 31, 2023. Portions of such proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.